News

The company said that duvelisib has shown clinical activity across a range of blood cancers, including indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). Currently, the safety

Apart from Sweden, ILUVIEN is currently approved for marketing in Austria, Denmark, France, Germany, Italy, Norway, Portugal, Spain and the UK, and is commercially available in the UK

In March 2000, the US Food and Drug Administration approved Zonegran as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Under the deal, Eisai

Under the deal, the two firms will work together to advance the next frontier of bi-specific antibody development platforms and bring new therapies to patients in need. CMC

On May 5, 2014, the U.S. Food and Drug Administration (FDA) expanded the indication of SYNRIBO to allow for home administration. SYNRIBO is a prescription medicine used to

Triumeq is a combination of the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine. Irrespective of racial origin, patients with

ALKS 3831 is composed of samidorphan, a new, potent mu-opioid antagonist, in combination with an antipsychotic drug, olanzapine. The trial is designed to evaluate the efficacy, safety and

Chimerix received the initial award in February 2011 which supported early research and development of brincidofovir in animal models of smallpox (Contract Number HHSO100201100013C). This contract extension provides

Orphan is a privately-held, Toronto-based specialty pharmaceutical company that in-licenses therapies for rare disorders and specialty medicines for the Canadian market. As part of the agreement, Jason Flowerday